HANOVER, N.H. — Boehringer Ingelheim this week provided more details about a late stage clinical trial of an app designed to treat under-addressed symptoms of schizophrenia and revealed the company is preparing to submit the app to the Food and Drug Administration for clearance.
Developed with Click Therapeutics, the app, CT-155 is a 16-week treatment that adapts key elements of established face-to-face psychosocial treatments for schizophrenia as an adjunct to antipsychotic drug treatment. Schizophrenia affects millions of people in the U.S. and is commonly associated with psychotic behavior and delusions. However, there are also common and often serious negative symptoms, including lack of motivation and the inability to experience pleasure, for which there are no approved drugs.
In topline results of a 464-participant randomized control trial first released in October, Boehringer Ingelheim revealed that users of the experimental app improved on a rating scale for these symptoms compared to a group that used a control app. Importantly, the treatment met its primary endpoint by passing a prespecified threshold for effect size.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
